| abstract |
The present invention induces an immune response by inducing immunogenic killing of tumor cells, and activates T cells or DC cells to directly promote host immunity, the mevalonic acid pathway in the manufacture of drugs to treat and/or prevent tumors It provides the use of inhibitors (mevalonic acid pathway inhibitors). In addition, the present invention provides a pharmaceutical composition comprising a mevalonic acid pathway inhibitor and an anti-tumor drug (e.g., an immune checkpoint inhibitor and any drug capable of causing new antigen production), and an anti- Tumor drugs (e.g., immune checkpoint inhibitors and any drugs that can result in the production of new antigens) and/or combination therapy with radiation therapy. |